9.6 Evaluation Following 60 Days Post-transplantation 
1. Monthly evaluations at transplant center for local 
patients for the first year post-transplant. 
Monthly evaluation to be conducted by referring 
physicians for patients who live elsewhere for 
first year post-transplant. Monthly evaluation to 
include CBC, platelet count, differential, 
electrolytes, liver function tests, quantitative 
immunoglobulins. Peripheral blood samples for PCR 
of FACS-sorted peripheral blood populations will 
also be obtained for similar analysis. 
Cytogenetics will be obtained if feasible. 
2 . Q 3 month evaluation at the transplant center for 
all patients for first year following 
transplantation. In addition to the above studies, 
bone marrow aspirate and biopsy will be performed 
for routine pathological examination including 
cytogenetics , PCR, FACS and clonogenic assays. 50 
cc of peripheral blood will be obtained for 
similar analysis. 
3. After the first year, identical analysis will be 
performed yearly for five years, and additionally 
at the time of any disease recurrence. 
10.0 Toxicity Monitoring 
10.1 For patients undergoing transplantation a careful daily 
assessment will be made with regard to organ specific 
toxicity. 
10.2 The Sandoz modification of the NCI Common Toxicity 
Criteria Scale will be used (see Appendix F) . 
10.3 The Dartmouth Transplant Criteria will be used to 
assess hematologic recovery post-transplantation (see 
appendix B) 
11.0 Dose modifications: 
11.1 Pre-transplant Interferon alpha (for toxicity levels 
see appendix E) 
Intolerable fatigue and anorexia 
Level 1: Decrease dose schedule to QOD. Maintain 
full dose. If progressive or persistent, hold dose 
until symptoms resolve, then dose reduce to 50% of 
the original dose on QOD. schedule; 
Recombinant DNA Research, Volume 16 
[169] 
